TAKHZYRO

takeda canada inc🇨🇦 Health Canada

Approval Id: ee96e9e56f6e9b30
Drug Approval Canada Name: TAKHZYRO
Product Name: TAKHZYRO
Status: Marketed
Status Date: 2022-02-28
Original Market Date: 2021-01-18
Din: 02505614
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Prescription , Schedule D
Ahfs: 92:32.00
Atc Original: B06AC05 LANADELUMAB
Atc Name: b 06 ac 05
Aig Number: 0160670001
Company Name: takeda canada inc
Company Address: 3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3

LANADELUMAB

300 MG / 2 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

ee96e9e56f6e9b30

Type

Standard